Vamil Divan
Stock Analyst at Guggenheim
(4.59)
# 155
Out of 4,784 analysts
225
Total ratings
62.25%
Success rate
15.72%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Initiates: Buy | $31 | $10.62 | +191.90% | 1 | Mar 25, 2025 | |
| ABSI Absci | Reiterates: Buy | $10 | $2.70 | +270.37% | 3 | Mar 20, 2025 | |
| PFE Pfizer | Reiterates: Buy | n/a | $25.21 | - | 22 | Mar 18, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $163.71 | - | 14 | Mar 12, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $84 → $86 | $67.61 | +27.20% | 9 | Mar 5, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $59 → $61 | $26.63 | +129.06% | 5 | Feb 27, 2025 | |
| INSM Insmed | Reiterates: Buy | $101 | $77.99 | +29.50% | 6 | Feb 25, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $122 → $115 | $89.23 | +28.88% | 13 | Feb 12, 2025 | |
| ABBV AbbVie | Maintains: Buy | $212 → $214 | $205.29 | +4.24% | 23 | Feb 3, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | n/a | $10.79 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $41 | $19.68 | +108.33% | 7 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.91 | +559.34% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.53 | - | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $8.28 | +141.55% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.30 | +8,663.06% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $1.00 | +800.00% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.17 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $17.07 | +11.31% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $113.16 | -13.40% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $33.21 | +2.38% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.55 | +545.16% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $118.53 | -58.66% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $822.51 | -56.72% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $5.58 | +7.53% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $27.65 | +456.96% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $12.05 | +24.48% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.46 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $15.08 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $3.38 | +343.79% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $60.02 | +1.63% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.50 | +6,766.67% | 3 | Jan 17, 2018 |
Assembly Biosciences
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $10.62
Upside: +191.90%
Absci
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.70
Upside: +270.37%
Pfizer
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.21
Upside: -
Johnson & Johnson
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $163.71
Upside: -
ANI Pharmaceuticals
Mar 5, 2025
Maintains: Buy
Price Target: $84 → $86
Current: $67.61
Upside: +27.20%
Vera Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $26.63
Upside: +129.06%
Insmed
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $77.99
Upside: +29.50%
Merck & Co.
Feb 12, 2025
Maintains: Buy
Price Target: $122 → $115
Current: $89.23
Upside: +28.88%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $212 → $214
Current: $205.29
Upside: +4.24%
Keros Therapeutics
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.79
Upside: -
Oct 9, 2024
Maintains: Buy
Price Target: $23 → $41
Current: $19.68
Upside: +108.33%
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.91
Upside: +559.34%
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.53
Upside: -
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $8.28
Upside: +141.55%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.30
Upside: +8,663.06%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.00
Upside: +800.00%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $17.07
Upside: +11.31%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $113.16
Upside: -13.40%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $33.21
Upside: +2.38%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.55
Upside: +545.16%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $118.53
Upside: -58.66%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $822.51
Upside: -56.72%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $5.58
Upside: +7.53%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $27.65
Upside: +456.96%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $12.05
Upside: +24.48%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $25.46
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $15.08
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $3.38
Upside: +343.79%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $60.02
Upside: +1.63%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.50
Upside: +6,766.67%